|
1
|
Jacobs JJ, Kieboom K, Marino S, DePinho RA
and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1
regulates cell proliferation and senescence through the ink4a
locus. Nature. 397:164–168. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song LB, Zeng MS, Liao WT, Zhang L, Mo HY,
Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al: Bmi-1 is a novel
molecular marker of nasopharyngeal carcinoma progression and
immortalizes primary human nasopharyngeal epithelial cells. Cancer
Res. 66:6225–6232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li J, Gong LY, Song LB, Jiang LL, Liu LP,
Wu J, Yuan J, Cai JC, He M, Wang L, et al: Oncoprotein Bmi-1
renders apoptotic resistance to glioma cells through activation of
the IKK-nuclear factor-kappaB pathway. Am J Pathol. 176:699–709.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo BH, Feng Y, Zhang R, Xu LH, Li MZ,
Kung HF, Song LB and Zeng MS: Bmi-1 promotes invasion and
metastasis, and its elevated expression is correlated with an
advanced stage of breast cancer. Mol Cancer. 10:102011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Itahana K, Zou Y, Itahana Y, Martinez JL,
Beausejour C, Jacobs JJ, Van Lohuizen M, Band V, Campisi J and
Dimri GP: Control of the replicative life span of human fibroblasts
by p16 and the polycomb protein Bmi-1. Mol Cell Biol. 23:389–401.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhattacharya R, Nicoloso M, Arvizo R, Wang
E, Cortez A, Rossi S, Calin GA and Mukherjee P: MiR-15a and MiR-16
control Bmi-1 expression in ovarian cancer. Cancer Res.
69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Honig A, Weidler C, Häusler S,
Krockenberger M, Buchholz S, Köster F, Segerer SE, Dietl J and
Engel JB: Overexpression of polycomb protein BMI-1 in human
specimens of breast, ovarian, endometrial and cervical cancer.
Anticancer Res. 30:1559–1564. 2010.PubMed/NCBI
|
|
8
|
Tong YQ, Liu B, Zheng HY, He YJ, Gu J, Li
F and Li Y: Overexpression of BMI-1 is associated with poor
prognosis in cervical cancer. Asia Pac J Clin Oncol. 8:e55–e62.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abdouh M, Facchino S, Chatoo W, Balasingam
V, Ferreira J and Bernier G: BMI1 sustains human glioblastoma
multiforme stem cell renewal. J Neurosci. 29:8884–8896. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK,
Choe IS, Choe YK and Kim JW: The Bmi-1 oncoprotein is overexpressed
in human colorectal cancer and correlates with the reduced
p16INK4a/p14ARF proteins. Cancer Lett. 203:217–224. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kreso A, van Galen P, Pedley NM,
Lima-Fernandes E, Frelin C, Davis T, Cao L, Baiazitov R, Du W,
Sydorenko N, et al: Self-renewal as a therapeutic target in human
colorectal cancer. Nat Med. 20:29–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Kemenade FJ, Raaphorst FM, Blokzijl T,
Fieret E, Hamer KM, Satijn DP, Otte AP and Meijer CJ: Coexpression
of BMI-1 and EZH2 polycomb-group proteins is associated with
cycling cells and degree of malignancy in B-cell non-Hodgkin
lymphoma. Blood. 97:3896–3901. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balasubramanian S, Lee K, Adhikary G,
Gopalakrishnan R, Rorke EA and Eckert RL: The Bmi-1 polycomb group
gene in skin cancer: Regulation of function by
(−)-epigallocatechin-3-gallate. Nutr Rev. 66:(Suppl 1). S65–S68.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui H, Hu B, Li T, Ma J, Alam G, Gunning
WT and Ding HF: Bmi-1 is essential for the tumorigenicity of
neuroblastoma cells. Am J Pathol. 170:1370–1378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin T, Wei H, Leng Z, Yang Z, Gou S, Wu H,
Zhao G, Hu X and Wang C: Bmi-1 promotes the chemoresistance,
invasion and tumorigenesis of pancreatic cancer cells.
Chemotherapy. 57:488–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lindström MS, Klangby U and Wiman KG:
p14ARF homozygous deletion or MDM2 overexpression in Burkitt
lymphoma lines carrying wild type p53. Oncogene. 20:2171–2177.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dhawan S, Tschen SI and Bhushan A: Bmi-1
regulates the Ink4a/Arf locus to control pancreatic beta-cell
proliferation. Genes Dev. 23:906–911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang L, Li J and Song L: Bmi-1, stem
cells and cancer. Acta Biochim Biophys Sin (Shanghai). 41:527–534.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bracken AP, Dietrich N, Pasini D, Hansen
KH and Helin K: Genome-wide mapping of Polycomb target genes
unravels their roles in cell fate transitions. Genes Dev.
20:1123–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan C, He L, Kapoor A, Rybak AP, De Melo
J, Cutz JC and Tang D: PTEN inhibits BMI1 function independently of
its phosphatase activity. Mol Cancer. 8:982009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kimura M, Takenobu H, Akita N, Nakazawa A,
Ochiai H, Shimozato O, Fujimura Y, Koseki H, Yoshino I, Kimura H,
et al: Bmi1 regulates cell fate via tumor suppressor WWOX
repression in small-cell lung cancer cells. Cancer Sci.
102:983–990. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao L, Bombard J, Cintron K, Sheedy J,
Weetall ML and Davis TW: BMI1 as a novel target for drug discovery
in cancer. J Cell Biochem. 112:2729–2741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yong KJ, Basseres DS, Welner RS, Zhang WC,
Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL,
Battelli C, et al: Targeted BMI1 inhibition impairs tumor growth in
lung adenocarcinomas with low CEBPα expression. Sci Transl Med.
8:350ra1042016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin T, Zhang Z, Cao B, Duan Q, Shi P, Zhao
H, Camara SN, Shen Q and Wang C: Bmi1 inhibition enhances the
sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget.
7:37192–37204. 2016.PubMed/NCBI
|
|
25
|
Mustafi S Banerjee, Chakraborty PK, Naz S,
Dwivedi SK, Street M, Basak R, Yang D, Ding K, Mukherjee P and
Bhattacharya R: MDR1 mediated chemoresistance: BMI1 and TIP60 in
action. Biochim Biophys Acta. 1859:983–993. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hastie CJ, Vázquez-Martin C, Philp A,
Stark MJ and Cohen PT: The Saccharomyces cerevisiae orthologue of
the human protein phosphatase 4 core regulatory subunit R2 confers
resistance to the anticancer drug cisplatin. FEBS J. 273:3322–3334.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen GI, Tisayakorn S, Jorgensen C,
D'Ambrosio LM, Goudreault M and Gingras AC: PP4R4/KIAA1622 forms a
novel stable cytosolic complex with phosphoprotein phosphatase 4. J
Biol Chem. 283:29273–29284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chowdhury D, Xu X, Zhong X, Ahmed F, Zhong
J, Liao J, Dykxhoorn DM, Weinstock DM, Pfeifer GP and Lieberman J:
A PP4-phosphatase complex dephosphorylates gamma-H2AX generated
during DNA replication. Mol Cell. 31:33–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakada S, Chen GI, Gingras AC and Durocher
D: PP4 is a gamma H2AX phosphatase required for recovery from the
DNA damage checkpoint. EMBO Rep. 9:1019–1026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Byun HJ, Kim BR, Yoo R, Park SY and Rho
SB: sMEK1 enhances gemcitabine anti-cancer activity through
inhibition of phosphorylation of Akt/mTOR. Apoptosis. 17:1095–1103.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bertram PG, Choi JH, Carvalho J, Ai W,
Zeng C, Chan TF and Zheng XF: Tripartite regulation of Gln3p by
TOR, Ure2p, and phosphatases. J Biol Chem. 275:35727–35733. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mihindukulasuriya KA, Zhou G, Qin J and
Tan TH: Protein phosphatase 4 interacts with and down-regulates
insulin receptor substrate 4 following tumor necrosis factor-alpha
stimulation. J Biol Chem. 279:46588–46594. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gingras AC, Caballero M, Zarske M, Sanchez
A, Hazbun TR, Fields S, Sonenberg N, Hafen E, Raught B and
Aebersold R: A novel, evolutionarily conserved protein phosphatase
complex involved in cisplatin sensitivity. Mol Cell Proteomics.
4:1725–1740. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH,
Wadzinski BE and Seto E: Histone deacetylase 3 (HDAC3) activity is
regulated by interaction with protein serine/threonine phosphatase
4. Genes Dev. 19:827–839. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoon YS, Lee MW, Ryu D, Kim JH, Ma H, Seo
WY, Kim YN, Kim SS, Lee CH, Hunter T, et al: Suppressor of MEK null
(SMEK)/protein phosphatase 4 catalytic subunit (PP4C) is a key
regulator of hepatic gluconeogenesis. Proc Natl Acad Sci USA.
107:17704–17709. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong SM, Byun HJ, Kim BR, Lee SH, Trink B
and Rho SB: Tumor suppressor BLU enhances pro-apoptotic activity of
sMEK1 through physical interaction. Cell Signal. 24:1208–1214.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim BR, Seo SH, Park MS, Lee SH, Kwon Y
and Rho SB: sMEK1 inhibits endothelial cell proliferation by
attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.
Oncotarget. 6:31830–31843. 2015.PubMed/NCBI
|
|
38
|
Rho SB, Song YJ, Lim MC, Lee SH, Kim BR
and Park SY: Programmed cell death 6 (PDCD6) inhibits angiogenesis
through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell
Signal. 24:131–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Glinsky GV: Stem cell origin of
death-from-cancer phenotypes of human prostate and breast cancers.
Stem Cell Rev. 3:79–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vrzalikova K, Skarda J, Ehrmann J, Murray
PG, Fridman E, Kopolovic J, Knizetova P, Hajduch M, Klein J, Kolek
V, et al: Prognostic value of Bmi-1 oncoprotein expression in NSCLC
patients: A tissue microarray study. J Cancer Res Clin Oncol.
134:1037–1042. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang H, Pan K, Zhang HK, Weng DS, Zhou J,
Li JJ, Huang W, Song HF, Chen MS and Xia JC: Increased
polycomb-group oncogene Bmi-1 expression correlates with poor
prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol.
134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ,
Li SX, Wang XL and Peng ZH: Expression level of Bmi-1 oncoprotein
is associated with progression and prognosis in colon cancer. J
Cancer Res Clin Oncol. 136:997–1006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gavrilescu MM, Todosi AM, Aniţei MG, Filip
B and Scripcariu V: Expression of bmi-1 protein in cervical, breast
and ovarian cancer. Rev Med Chir Soc Med Nat Iasi. 116:1112–1117.
2012.PubMed/NCBI
|
|
44
|
Chobanian N and Dietrich CS III: Ovarian
cancer. Surg Clin North Am. 88285–299. (vi)2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lakhani SR, Manek S, Penault-Llorca F,
Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P,
Klijn JG, et al: Pathology of ovarian cancers in BRCA1 and BRCA2
carriers. Clin Cancer Res. 10:2473–2481. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stavropoulou AV, Fostira F, Pertesi M,
Tsitlaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos
MA, Timotheadou E, Pectasides D, et al: Prevalence of BRCA1
mutations in familial and sporadic Greek ovarian cancer cases. PLoS
One. 8:e581822013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shih KK and Chi DS: Maximal cytoreductive
effort in epithelial ovarian cancer surgery. J Gynecol Oncol.
21:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ozols RF: Treatment goals in ovarian
cancer. Int J Gynecol Cancer 15 (Suppl 1). 3–11. 2005. View Article : Google Scholar
|
|
50
|
Spannuth WA, Nick AM, Jennings NB,
Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker
PH, Kamat AA, et al: Functional significance of VEGFR-2 on ovarian
cancer cells. Int J Cancer. 124:1045–1053. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang E, Bhattacharyya S, Szabolcs A,
Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P,
Sood AK and Bhattacharya R: Enhancing chemotherapy response with
Bmi-1 silencing in ovarian cancer. PLoS One. 6:e179182011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xin T, Zhang FB, Sui GJ and Jin XM: Bmi-1
siRNA inhibited ovarian cancer cell line growth and decreased
telomerase activity. Br J Biomed Sci. 69:62–66. 2012.PubMed/NCBI
|
|
53
|
Gao FL, Li WS, Liu CL and Zhao GQ:
Silencing Bmi-1 enhances the senescence and decreases the
metastasis of human gastric cancer cells. World J Gastroenterol.
19:8764–8769. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang Y, Zhang YL, Chen HM, Pu HW, Ma WJ,
Li XM, Ma H and Chen X: Expression of Bmi-1 and PAI-1 in esophageal
squamous cell carcinoma. World J Gastroenterol. 20:5533–5539. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G
and Wang Y: Overexpression of BMI-1 promotes cell growth and
resistance to cisplatin treatment in osteosarcoma. PLoS One.
6:e146482011. View Article : Google Scholar : PubMed/NCBI
|
